Immuneering Corporation Announces Grants of Inducement Awards
Rhea-AI Summary
Immuneering (Nasdaq: IMRX) granted stock options as inducement awards tied to new hires effective July 16, 2026. New Chief Financial Officer Andrew Gengos received an option to purchase 650,000 Class A common shares at an exercise price of $4.78, equal to the July 16, 2026 Nasdaq closing price. The ten-year option, issued under the 2025 Employment Inducement Award Plan and approved by the Board, vests monthly over four years, becoming fully vested on the fourth anniversary of his start date.
On the same date, a non-executive employee received an option for 32,400 shares at the same exercise price, vesting 25% on July 16, 2027 and the remaining 75% in substantially equal monthly installments through July 16, 2030. Both grants were made under Nasdaq Rule 5635(c)(4) as material inducements to employment.
Positive
- None.
Negative
- None.
News Market Reaction – IMRX
In the Jul 20 session, IMRX declined 7.54%, reflecting a notable negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jun 15 | CFO appointment | Neutral | +0.0% | Andrew Gengos was appointed CFO, effective July 16, 2026. |
| Jun 11 | Phase 3 dosing | Positive | +5.1% | MAPKeeper 301 dosed its first patient in metastatic pancreatic cancer. |
| Jun 01 | Clinical data update | Positive | -22.1% | ASCO data reported 17.3-month median overall survival and favorable tolerability. |
| May 21 | Clinical data update | Positive | +0.4% | Phase 2a data reported 17.3-month median overall survival in pancreatic cancer. |
| May 15 | First-quarter earnings | Positive | +0.4% | Q1 results reported $198.6 million in cash and runway into 2029. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
The stock’s prior news reactions were generally aligned with positive announcements, except for a 22.1% decline after positive ASCO data.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK, July 17, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, previously announced on June 15, 2026, that Andrew Gengos was named Chief Financial Officer of the Company, effective as of July 16, 2026 (the “Start Date”). In connection with the commencement of Mr. Gengos’s employment, on July 16, 2026, Mr. Gengos was granted an option to purchase 650,000 shares of the Company’s Class A common stock (“Common Stock”) with a per share exercise price of
Additionally, in connection with the commencement of employment of a non-executive employee, also on July 16, 2026, such employee was granted an option to purchase 32,400 shares of Common Stock with a per share exercise price equal to the Closing Price. The stock option was granted pursuant to the Inducement Plan and was approved by the Compensation Committee of the Board. The stock option has a ten-year term and vests (subject to the employee’s continued service to the Company through the applicable vesting dates)
About Immuneering Corporation
Immuneering is a late-stage clinical oncology company dedicated to keeping cancer patients alive and helping them thrive, with an initial focus on patients with RAS, RAF, and other MAPK-driven cancers. The Company is developing an entirely new category of cancer medicines, Deep Cyclic Inhibitors, designed to improve overall survival by three mechanisms: shrinking tumors durably with less resistance, preserving body mass by countering cachexia, and minimizing side effects to maximize performance status and combinability. Immuneering’s lead product candidate, atebimetinib, is an investigational, oral, once-daily Deep Cyclic Inhibitor of MEK, designed to improve survival across many cancer indications. The company is conducting a global randomized pivotal trial, MAPKeeper 301, evaluating atebimetinib in combination with chemotherapy in first-line pancreatic cancer patients. The Company’s development pipeline also includes additional combination opportunities and preclinical stage programs. For more information, please visit www.immuneering.com.
Forward Looking Statements
This press release contains forward-looking statements, including within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding: Immuneering’s plans to develop, and the treatment potential of, its product candidates.
These forward-looking statements are based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: the risks inherent in oncology drug research and development, including target discovery, target validation, lead compound identification, and lead compound optimization; we have incurred significant losses, are not currently profitable and may never become profitable; our projected cash runway; our need for additional funding; our unproven approach to therapeutic intervention; our ability to address regulatory questions and the uncertainties relating to regulatory filings, reviews and approvals; the lengthy, expensive, and uncertain process of clinical drug development, including potential delays in activating trial sites or enrolling trial participants, or failure to obtain regulatory approvals; our reliance on third parties and collaborators to conduct our clinical trials, manufacture our product candidates, and develop and commercialize our product candidates, if approved; failure to compete successfully against other drug companies; protection of our proprietary technology and the confidentiality of our trade secrets; potential lawsuits for, or claims of, infringement of third-party intellectual property or challenges to the ownership of our intellectual property; our patents being found invalid or unenforceable; costs and resources of operating as a public company; and unfavorable or no analyst research or reports.
These and other important factors discussed under the caption “Risk Factors” in our Quarterly Report on Form 10-Q for the period ended March 31, 2026, and our other reports filed with the U.S. Securities and Exchange Commission, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, except as required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.
Investor Contact:
Laurence Watts
laurence@newstreetir.com
Media Contact:
David Caouette
dcaouette@immuneering.com
